This is a post-marketing, non-interventional study of participants with moderate to severe UC. The study will review medical records of participants who have initiated medical treatment with vedolizumab intravenous during the defined eligibility period under routine clinical practice to provide the real world data on the effectiveness and safety of vedolizumab intravenous.
The study will enroll approximately 100 participants. All participants will be enrolled in one observational group: Vedolizumab
Both retrospective and prospective data will be collected in the index period, with prospective data collected for treatment baseline visit and follow up visits.
The multi-center trial will be conducted in Republic of Korea. The overall duration of study will be approximately 15 months.
